NZ758333B2 - Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors - Google Patents

Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors

Info

Publication number
NZ758333B2
NZ758333B2 NZ758333A NZ75833318A NZ758333B2 NZ 758333 B2 NZ758333 B2 NZ 758333B2 NZ 758333 A NZ758333 A NZ 758333A NZ 75833318 A NZ75833318 A NZ 75833318A NZ 758333 B2 NZ758333 B2 NZ 758333B2
Authority
NZ
New Zealand
Prior art keywords
cancer
use according
cell lymphoma
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
NZ758333A
Other versions
NZ758333A (en
Inventor
Subramanya Hosahalli
Kavitha Nellore
Original Assignee
Aurigene Oncology Limited
Filing date
Publication date
Priority claimed from US15/494,820 external-priority patent/US9937155B2/en
Priority claimed from US15/899,707 external-priority patent/US20180369206A1/en
Application filed by Aurigene Oncology Limited filed Critical Aurigene Oncology Limited
Publication of NZ758333A publication Critical patent/NZ758333A/en
Publication of NZ758333B2 publication Critical patent/NZ758333B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

The present invention provides methods for treating a cancer in a subject and for inhibiting tumor growth, metastasis or a dihydrorotate oxygenase enzyme activity of a tumor or cancer cell. At least one trisubstituted benzotriazole derivative with the formula (I) is administered to the subject or is contacted with the cancer cell. Compounds of formula (I) have substituents R1, R2and R3which have the meanings given in the specification, and pharmaceutically acceptable salts thereof.

Claims (23)

Claims:
1. Use of a compound selected from: O OH O NH O OH O OH O OH O NH O OH O OH O OH O NH O OH O OH HO O HO O HO O HO O HO O HO O O OH HO O HO O HO O , and , or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a cancer selected from acute myeloid leukemia, multiple myeloma, B- prolymphocytic leukemia, chronic lymphocytic leukemia, Hodgkin’s disease, non- Hodgkin’s lymphoma, follicular lymphoma, diffuse large B cell lymphoma, anaplastic large cell lymphoma, mantle cell lymphoma, triple negative breast cancer, melanoma, prostate cancer, and cancer of the esophagus.
2. The use according to claim 1, wherein the cancer is acute myeloid leukemia.
3. The use according to claim 1, wherein the cancer is multiple myeloma.
4. The use according to claim 1, wherein the cancer is B-prolymphocytic leukemia.
5. The use according to claim 1, wherein the cancer is non-Hodgkin’s lymphoma.
6. The use according to claim 1, wherein the cancer is diffuse large B cell lymphoma.
7. The use according to claim 6, wherein the diffuse large B cell lymphoma is double hit diffuse large B cell lymphoma.
8. The use according to claim 6, wherein the diffuse large B cell lymphoma is triple hit diffuse large B cell lymphoma.
9. The use according to claim 1, wherein the cancer is anaplastic large cell lymphoma.
10. The use according to claim 1, wherein the cancer is mantle cell lymphoma.
11. The use according to claim 1, wherein the cancer is triple negative breast cancer.
12. The use according to claim 1, wherein the cancer is melanoma.
13. The use according to claim 1, wherein the cancer is prostate cancer.
14. The use according to claim 1, wherein the cancer is cancer of the esophagus.
15. The use according to claim 1, wherein the cancer is chronic lymphocytic leukemia.
16. The use according to claim 1, wherein the cancer is Hodgkin’s disease.
17. The use according to claim 1, wherein the cancer is follicular lymphoma.
18. The use according to any one of claims 1-17, wherein the compound is or a pharmaceutically acceptable salt thereof.
19. The use according to any one of claims 1-17, wherein the compound is or a pharmaceutically acceptable salt thereof.
20. The use according to any one of claims 1-17, wherein the compound is or a pharmaceutically acceptable salt thereof.
21. The use according to any one of claims 1-17, wherein the compound is or a pharmaceutically acceptable salt thereof.
22. The use according to any one of claims 1-17, wherein the compound is or a pharmaceutically acceptable salt thereof.
23. The use according to any one of claims 1-17, wherein the compound is or a pharmaceutically acceptable salt thereof. Aurigene Oncology Limited By the Attorneys for the Applicant SPRUSON & FERGUSON
NZ758333A 2018-04-19 Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors NZ758333B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/494,820 US9937155B2 (en) 2013-02-25 2017-04-24 Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
US15/899,707 US20180369206A1 (en) 2017-04-24 2018-02-20 Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
PCT/IB2018/052710 WO2018197997A1 (en) 2017-04-24 2018-04-19 Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors

Publications (2)

Publication Number Publication Date
NZ758333A NZ758333A (en) 2025-10-31
NZ758333B2 true NZ758333B2 (en) 2026-02-03

Family

ID=

Similar Documents

Publication Publication Date Title
RS20230516A1 (en) Methods of treating prostate cancer
MX2023000333A (en) Salts and forms of a wee1 inhibitor.
PH12017502407B1 (en) Fused pyrimidine compound or salt thereof
GEP20227359B (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
WO2019169065A3 (en) Wee1 kinase inhibitors and methods of treating cancer using the same
WO2013053983A8 (en) Protein kinase inhibitors
WO2018102452A3 (en) Using substituted pyrazole compounds for treatment of hyperproliferative diseases
MY183661A (en) Treatment of cancer with tor kinase inhibitors
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
EA201391337A1 (en) HSP90 INHIBITORS
WO2011141716A3 (en) Modulators of chk-1 activity
PH12015501585A1 (en) Manufacturing process for pyrimidine derivatives
WO2012141796A3 (en) Prostate cancer therapy with hsp90 inhibitory compounds
ZA202401684B (en) Novel parp7 inhibitor and use thereof
MX2022014192A (en) Methods of treating prostate cancer.
PH12019502402A1 (en) Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
MX2020010437A (en) Axl kinase inhibitors and use of the same.
PH12014501832A1 (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
PH12021552579A1 (en) Compounds with anti-tumor activity against cancer cells bearing tyrosine kinase inhibitor resistant egfr mutations
EA200800516A1 (en) DERIVATIVES N-PHENYL-2-PYRIMIDINAMINE AND THE PROCESS OF THEIR RECEPTION
MX2025011125A (en) Triazine compound and use thereof
WO2014169882A3 (en) Benzimidazole-type compound exhibiting anti-tumor activity, preparation method and use thereof
NZ758333B2 (en) Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
PH12021552110A1 (en) Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions
MX2024000610A (en) Therapeutic compounds and methods.